RxDoctor Payments Data

Mavis Twum Barimah, MD

Family Medicine · Odessa, TXNPI 1376807362

Payments from drug & device makers

$331in general payments, 2019–2025

Across 15 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$149
  • Astellas Pharma US Inc$72
  • AstraZeneca$28
  • Xeris Pharmaceuticals, Inc.$20
  • Dexcom, Inc.$19
  • Amgen$16
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$27082%
  • Education$6118%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$331 in reported general payments places this provider in the 40th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$1,146
Medicare patients
54
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$73,199
MounjaroTirzepatide45$64,236
JardianceEmpagliflozin42$62,135
RybelsusSemaglutide26$54,099
EliquisApixaban43$43,939
FarxigaDapagliflozin Propanediol21$36,504
JanuviaSitagliptin Phosphate24$35,294
SynjardyEmpagliflozin/Metformin Hcl19$23,247
TrulicityDulaglutide12$21,761
Xigduo XrDapaglifloz Propaned/Metformin11$21,729
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$19,435
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$17,907
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$17,345
Breo ElliptaFluticasone/Vilanterol26$16,529
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$15,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$14$127,29873 claims
Lilly USA, LLCMounjaro, Trulicity$149$85,99857 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$28$55,91949 claims
Astellas Pharma US IncMyrbetriq$72$13,60816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Odessa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →